You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH):迪耳藥業25%股權由海南亞洲製藥以3577.25萬元摘牌
格隆匯 02-07 18:09

格隆匯2月7日丨康恩貝(600572.SH)公佈,此前披露,公司控股子公司金華康恩貝以不低於35,772,506元的掛牌價繼續轉讓迪耳藥業25%股權。2022年1月25日,迪耳藥業的控股股東海南亞洲製藥股份有限公司(海南亞洲製藥,持有迪耳藥業52.73%股權)通過浙江產權交易所公開摘牌受讓迪耳藥業25%股權,成交價格為3577.25萬元。

2022年1月29日,金華康恩貝與海南亞洲製藥簽署了《浙江迪耳藥業有限公司25%股權交易合同》。本次股權轉讓交易完成後,金華康恩貝將不再持有迪耳藥業股權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account